201 related articles for article (PubMed ID: 35980831)
41. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
[TBL] [Abstract][Full Text] [Related]
42. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
Trump DL
Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
[TBL] [Abstract][Full Text] [Related]
43. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer.
Terrisse S; Goubet AG; Ueda K; Thomas AM; Quiniou V; Thelemaque C; Dunsmore G; Clave E; Gamat-Huber M; Yonekura S; Ferrere G; Rauber C; Pham HP; Fahrner JE; Pizzato E; Ly P; Fidelle M; Mazzenga M; Costa Silva CA; Armanini F; Pinto F; Asnicar F; Daillère R; Derosa L; Richard C; Blanchard P; Routy B; Culine S; Opolon P; Silvin A; Ginhoux F; Toubert A; Segata N; McNeel DG; Fizazi K; Kroemer G; Zitvogel L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296557
[TBL] [Abstract][Full Text] [Related]
44. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.
Sharifi N; Kawasaki BT; Hurt EM; Farrar WL
Cancer Biol Ther; 2006 Aug; 5(8):901-6. PubMed ID: 16855379
[TBL] [Abstract][Full Text] [Related]
45. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
46. Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition.
Pelliccia A; Capradossi F; Corsi F; Tarquini GD; Bruni E; Reichle A; Torino F; Ghibelli L
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768364
[TBL] [Abstract][Full Text] [Related]
47. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
48. Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
Deka R; Rose BS; Bryant AK; Sarkar RR; Nalawade V; McKay R; Murphy JD; Simpson DR
Cancer; 2019 Apr; 125(7):1070-1080. PubMed ID: 30748008
[TBL] [Abstract][Full Text] [Related]
49. Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin.
Yang B; Damodaran S; Khemees TA; Filon MJ; Schultz A; Gawdzik J; Etheridge T; Malin D; Richards KA; Cryns VL; Jarrard DF
Mol Cancer Ther; 2020 Nov; 19(11):2278-2287. PubMed ID: 32943543
[TBL] [Abstract][Full Text] [Related]
50. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
51. miRNAs and androgen deprivation therapy for prostate cancer.
Konoshenko MY; Bryzgunova OE; Laktionov PP
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188625. PubMed ID: 34534639
[TBL] [Abstract][Full Text] [Related]
52. Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.
Kohli M; Oberg AL; Mahoney DW; Riska SM; Sherwood R; Zhang Y; Zenka RM; Sahasrabudhe D; Qin R; Zhang S
Clin Genitourin Cancer; 2019 Aug; 17(4):248-253.e7. PubMed ID: 31103340
[TBL] [Abstract][Full Text] [Related]
53. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
54. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
55. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.
Mooso BA; Vinall RL; Tepper CG; Savoy RM; Cheung JP; Singh S; Siddiqui S; Wang Y; Bedolla RG; Martinez A; Mudryj M; Kung HJ; Devere White RW; Ghosh PM
Endocr Relat Cancer; 2012 Dec; 19(6):759-77. PubMed ID: 22993077
[TBL] [Abstract][Full Text] [Related]
56. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
57. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
Liu S; Qi Y; Ge Y; Duplessis T; Rowan BG; Ip C; Cheng H; Rennie PS; Horikawa I; Lustig AJ; Yu Q; Zhang H; Dong Y
Mol Cancer Ther; 2010 Jul; 9(7):2016-25. PubMed ID: 20571066
[TBL] [Abstract][Full Text] [Related]
58. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
[TBL] [Abstract][Full Text] [Related]
59. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
Cardoso HJ; Figueira MI; Vaz CV; Carvalho TMA; Brás LA; Madureira PA; Oliveira PJ; Sardão VA; Socorro S
Cell Oncol (Dordr); 2021 Apr; 44(2):385-403. PubMed ID: 33464483
[TBL] [Abstract][Full Text] [Related]
60. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
Nishiyama T
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
